Medable Forms New Site Network Council for DCTs
Medable Inc. has announced its Site Network Council (SNC), a select group of clinicians and research leaders who will serve as influential voices in Medable product and services development. SNC members represent diverse clinical sites and provide real-world experience and insights to inform Medable technical and strategic direction. They offer a transparent window into modern research environments to help Medable create decentralized clinical trial workflows that meet sites’ changing needs and enable greater participation in DCTs.
Medable’s SNC has eight founding members, representing a diverse community of site leaders across the U.S. with plans to expand into the EU by Q4 2021. SNC members also represent a variety of settings from academia to healthcare providers to dedicated research centers, and include principal investigators, study coordinators, and executive leadership with a combined professional experience of over 150 years.
The SNC’s mission is to ensure Medable products meet the needs of all site stakeholders. Members will regularly review training, workflows, and user interfaces and participate in reviews of study approaches prior to study launch to ensure maximum site value.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
